SciClone Pharmaceuticals (Holdings) Limited (6600.HK)

18,320 -0,100 (-0,54%) Börsenschluss: 04:08PM HKT

SciClone Pharmaceuticals (Holdings) Limited

Central Plaza
22nd Floor 381 Middle Huaihai Road
Shanghai
China
86 21 2319 3800
https://www.sciclone.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 1.050

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Hong Zhao	CEO, President & Executive Director	8,55M	N/A	1963
Ms. Rongrong Pan	Company Secretary, CFO & Executive Director	N/A	N/A	1979
Mr. Chihwen Shao	VP & Head of Technical Operations and Pharmacovigilance	N/A	N/A	1963
Mr. Min Jia	VP & Head of Immunization Business Unit	N/A	N/A	1971
Mr. Yansong Chang	VP & GM of Oncology Business Unit	N/A	N/A	1969
Mr. Mingxiang Wu	VP and Head of Market Access & Commercial Operation (MACO) Department	N/A	N/A	1967
Dr. Xiaoning Guo	VP, Head of Research & Development Department and Chief Medical Officer	N/A	N/A	1978
Mr. Lianzong Wu	VP and Head of Registration & Pharmaceutical Affairs Department	N/A	N/A	1976
Dr. Li Mao M.D.	VP, GM of Research and Development & Chief Medical Officer	N/A	N/A	1957
Dr. Min Wu	VP & Chief Business Development Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in HKD.

Beschreibung

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of chronic hepatitis B. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma. The company's pipeline products comprise Vibativ for the treatment of hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic, which treats solid tumors; PEN-866, a drug conjugate for solid tumors; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.

Corporate Governance

SciClone Pharmaceuticals (Holdings) Limiteds ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.